Patient description: The patient is a 55 year old man visiting his primary care physician for lower urinary tract symptoms including frequency, urgency, weak stream, incomplete emptying and intermittent flow for the past 9 months. Further evaluation revealed: IPSS score : 15 Post-void residual: 70 mL Prostate volume (TRUS): 60 mL Prostate-specific antigen (PSA) level: 3.2 ng/mL 10 mL/sec of maximum flow rate when urine volume was 130 mL He is otherwise healthy only using Vit D 1000 units daily. His recent blood chemistry (3 days ago) was normal: Hgb: 13.5 g/dl WBC: 135000 /mm3 Plt: 350000 /ml PT: 11 second PTT: 35 second INR: 0.9 Creatinine: 0.5 mg/dl BUN: 10 mg/dl U/A: Color: yellow Appearance: cloudy PH: 5.3 Specific gravity: 1.010 Glc: 100 Nitrite: negative Ketone: none Leukocyte esterase: negative RBC: negative WBC: 2 WBCs/hpf U/C: negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Hypogonadism Male, 18 to 65 years of age, inclusive, with a diagnosis of hypogonadism and a screening total serum T of < 300 ng/dL. 2. Adequate venous access to allow blood sample collections via venous cannula. 3. Naïve to androgen-replacement therapy or willing to temporarily cease current T treatment and willing to remain off all forms of T except for study medication throughout study. 4. Voluntarily provide written informed consent to participate in this study  Subjects meeting any of the following will not be eligible: 1. Significant intercurrent disease (especially liver, kidney, heart disease, uncontrolled diabetes mellitus or psychiatric illness) 2. Abnormal prostate digital rectal examination, elevated PSA (PSA > 4 ng/mL), AUA Symptom Score ≥ 15 points and/or history of prostate CA. 3. BMI less than 18 kg/m2 or greater than 37 kg/m2 4. Serum transaminases > 2 times upper limit of normal (ULN) or serum bilirubin >2.0 mg/dL. 5. History of severe or multiple allergies, or severe adverse drug reaction. A known hypersensitivity to lidocaine or all surgical dressings which may be used in the study procedures. 6. History of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation. 7. Oral, topical or buccal T therapy within previous one week, or intramuscular T injection within previous 4 weeks. 8. Parenteral T-undecanoate therapy within the past 6 months. 9. Use of dietary supplements that may increase serum T, within previous 4 weeks. 10. Known malabsorption syndrome and/or current treatment with oral lipase inhibitors, bile acid-binding resins, colestipol, fibric acid derivatives, clofibrate, gemfibrozil, and probucol. 11. Smokers unable to refrain from smoking during required confinement period. 12. History of, or current evidence of, abuse of alcohol or any drug substance. 13. Receipt of any research study drug within 30 days of study. 14. Blood donation within the 12 week period before the initial study dose. 15. Hematocrit less than 35% or greater than 50%. 16. History of clinically significant polycythemia following treatment with a testosterone replacement product. 17. Current use of paroxetine, clomipramine, antiandrogens, estrogens, potent P450 enzyme inducers, or barbiturates. 18. History of uncontrolled sleep apnea